Value proposition reimbursement pathways for a DTx

A digital therapeutics company hired CRA to understand a medical device price and market access (PMA) potential for an at-home biomarker monitoring device across key European markets.

CRA approach

  • Evaluated relevant digital therapeutic analogues to establish the likely reimbursement and funding pathways for a novel eHealth product.
  • Determined the medical device price and market access potential in key markets for digital therapeutic companies as well as evidence requirements to achieve optimal pricing and access outcomes.
  • Assessed payer receptivity to alternative commercial medical device models including subscription-based payments.

Client impact

  • Identified reimbursement coding pathway to pursue in order to achieve expedited coverage.
  • Restructured pricing business model to capture untapped market segments for digital therapeutics.
Related capabilities

Meet our team